BioSpace News Archive

SCG Cell Therapy Pte Ltd presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell Therapy – SCG101 – at the International Society for Cell & Gene Therapy conference in Paris, France.

ImmunoGen Inc. announced detailed results from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer.

Summit Therapeutics Inc. announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today from 8:00 to 11:00am at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Amgen announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago.

G1 Therapeutics, Inc., a commercial-stage oncology company, presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer prior to receiving trilaciclib and neoadjuvant therapy.

Bristol Myers Squibb announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo plus Yervoy with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with metastatic non-small cell lung cancer.

Day One Biopharmaceuticals announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib.

This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma or ocular hypertension.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role.

VITRAC Therapeutics, LLC presented a poster on the Phase 1a/1b clinical trial of aurora kinase A inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib.